Forty Sev­en adds No­bel win­ner Jim Al­li­son to a dream team of sci­en­tif­ic ad­vis­ers

Forty Sev­en has added im­munol­o­gy su­per­star and new­ly mint­ed No­bel lau­re­ate Jim Al­li­son to its ad­vi­so­ry team.

The im­muno-on­col­o­gy start­up said Wednes­day that Al­li­son will be join­ing its sci­en­tif­ic ad­vi­so­ry board, along with three oth­er heavy­weights from the re­search world: Stan­ford’s Ronald Levy, MD An­der­son’s Pad­ma­nee Shar­ma, and George­town’s Louis Wein­er.

Ronald Levy

The dream-team ad­vis­ers will be guid­ing Forty Sev­en on de­vel­op­ment of its lead prod­uct, an in­ves­ti­ga­tion­al mon­o­clon­al an­ti­body known as 5F9. The an­ti­body tar­gets the CD47 re­cep­tor, which the com­pa­ny de­scribes as “a ‘don’t eat me re­cep­tor’ sig­nal that can­cer cells com­man­deer to avoid be­ing in­gest­ed by mi­crophages.” 5F9 is cur­rent­ly in Phase I/II test­ing for a va­ri­ety of can­cers.

Pad­ma­nee Shar­ma

Ear­li­er this week, Al­li­son was named a 2018 win­ner of the No­bel prize for phys­i­ol­o­gy and med­i­cine for his work on un­der­stand­ing the in­hi­bi­tion of neg­a­tive im­mune reg­u­la­tion in can­cer ther­a­py. Al­li­son cur­rent­ly serves as di­rec­tor of the Park­er In­sti­tute for Can­cer Re­search and ex­ec­u­tive di­rec­tor of Im­munother­a­py Plat­form at Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter. He shared the prize with Tasuku Hon­jo of Ky­oto Uni­ver­si­ty.

Louis Wein­er

Al­li­son will be joined on the board by Levy, whose im­munother­a­py re­search led to the de­vel­op­ment of the block­buster ther­a­py rit­ux­imab; Shar­ma, a top clin­i­cal in­ves­ti­ga­tor in im­munother­a­py who’s mar­ried to Al­li­son; and Wein­er, a lead­ing mon­o­clon­al an­ti­body re­searcher. 

Mark Mc­Camish

“Each of these ap­pointees is rec­og­nized world­wide as a pi­o­neer in de­vel­op­ing nov­el ther­a­peu­tics that mo­bi­lize pa­tient’s im­mune sys­tems to fight dis­ease,” says Forty Sev­en CEO Mark Mc­Camish, in a state­ment.  We look for­ward to work­ing close­ly to­geth­er to ex­pand our un­der­stand­ing of macrophage ac­ti­va­tion as a new modal­i­ty for treat­ing can­cer and to ad­vance 5F9 for­ward as a mon­o­clon­al an­ti­body against CD47, with po­ten­tial in mul­ti­ple on­col­o­gy in­di­ca­tions.”

Found­ed by Stan­ford Uni­ver­si­ty lu­mi­nary Irv Weiss­man, Forty Sev­en raised $116.3 mil­lion from its ini­tial pub­lic of­fer­ing in Ju­ly. The com­pa­ny is cur­rent­ly run­ning a Phase Ib clin­i­cal tri­al with Ger­many’s Mer­ck KGaA eval­u­at­ing 5F9 in com­bi­na­tion with Mer­ck’s avelum­ab in the treat­ment of ovar­i­an can­cer.


Im­age: Jim Al­li­son. MD AN­DER­SON

Drug man­u­fac­tur­ing gi­ant Lon­za taps Roche/phar­ma ‘rein­ven­tion’ vet as its new CEO

Lonza chairman Albert Baehny took his time headhunting a new CEO for the company, making it absolutely clear he wanted a Big Pharma or biotech CEO with a good long track record in the business for the top spot. In the end, he went with the gold standard, turning to Roche’s ranks to recruit Pierre-Alain Ruffieux for the job.

Ruffieux, a member of the pharma leadership team at Roche, spent close to 5 years at the company. But like a small army of manufacturing execs, he gained much of his experience at the other Big Pharma in Basel, remaining at Novartis for 12 years before expanding his horizons.

Is a pow­er­house Mer­ck team prepar­ing to leap past Roche — and leave Gilead and Bris­tol My­ers be­hind — in the race to TIG­IT dom­i­na­tion?

Roche caused quite a stir at ASCO with its first look at some positive — but not so impressive — data for their combination of Tecentriq with their anti-TIGIT drug tiragolumab. But some analysts believe that Merck is positioned to make a bid — soon — for the lead in the race to a second-wave combo immuno-oncology approach with its own ambitious early-stage program tied to a dominant Keytruda.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Fangliang Zhang, AP Images

UP­DAT­ED: Leg­end fetch­es $424 mil­lion, emerges as biggest win­ner yet in pan­dem­ic IPO boom as shares soar

Amid a flurry of splashy pandemic IPOs, a J&J-partnered Chinese biotech has emerged with one of the largest public raises in biotech history.

Legend Biotech, the Nanjing-based CAR-T developer, has raised $424 million on NASDAQ. The biotech had originally filed for a still-hefty $350 million, based on a range of $18-$20, but managed to fetch $23 per share, allowing them to well-eclipse the massive raises from companies like Allogene, Juno, Galapagos, though they’ll still fall a few dollars short of Moderna’s record-setting $600 million raise from 2018.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,200+ biopharma pros reading Endpoints daily — and it's free.

As it hap­pened: A bid­ding war for an an­tibi­ot­ic mak­er in a mar­ket that has rav­aged its peers

In a bewildering twist to the long-suffering market for antibiotics — there has actually been a bidding war for an antibiotic company: Tetraphase.

It all started back in March, when the maker of Xerava (an FDA approved therapy for complicated intra-abdominal infections) said it had received an offer from AcelRx for an all-stock deal valued at $14.4 million.

The offer was well-timed. Xerava was approved in 2018, four years after Tetraphase posted its first batch of pivotal trial data, and sales were nowhere near where they needed to be in order for the company to keep its head above water.

David Meline (file photo)

Mod­er­na’s new CFO took a cut in salary to jump to the mR­NA rev­o­lu­tion­ary. But then there’s the rest of the com­pen­sa­tion pack­age

David Meline took a little off the top of his salary when he jumped from the CFO post at giant Amgen to become the numbers czar at the upstart vaccines revolutionary Moderna. But the SEC filing that goes with a major hire also illustrates how it puts him in line for a fortune — provided the biotech player makes good as a promising game changer.

To be sure, there’s nothing wrong with the base salary: $600,000. Or the up-to 50% annual cash bonus — an industry standard — that comes with it. True, the 62-year-old earned $999,000 at Amgen in 2019, but it’s the stock options that really count in the current market bliss for all things biopharma. And there Meline did well.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,200+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Ab­b­Vie jumps in­to Covid-19 an­ti­body hunt; As­traZeneca shoots for 2B dos­es of Ox­ford vac­cine — with $750M from CEPI, Gavi

Another Big Pharma is entering the Covid-19 antibody hunt.

AbbVie has announced a collaboration with the Netherlands’ Utrecht University and Erasmus Medical Center and the Chinese-Dutch biotech Harbour Biomed to develop a neutralizing antibody that can treat Covid-19. The antibody, called 47D11, was discovered by AbbVie’s three partners, and AbbVie will support early preclinical work, while preparing for later preclinical and clinical development. Researchers described the antibody in Nature Communications last month.

Pfiz­er’s Doug Gior­dano has $500M — and some ad­vice — to of­fer a cer­tain breed of 'break­through' biotech

So let’s say you’re running a cutting-edge, clinical-stage biotech, probably public, but not necessarily so, which could see some big advantages teaming up with some marquee researchers, picking up say $50 million to $75 million dollars in a non-threatening minority equity investment that could take you to the next level.

Doug Giordano might have some thoughts on how that could work out.

The SVP of business development at the pharma giant has helped forge a new fund called the Pfizer Breakthrough Growth Initiative. And he has $500 million of Pfizer’s money to put behind 7 to 10 — or so — biotech stocks that fit that general description.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,200+ biopharma pros reading Endpoints daily — and it's free.

Bris­tol My­ers is clean­ing up the post-Cel­gene merg­er pipeline, and they’re sweep­ing out an ex­per­i­men­tal check­point in the process

Back during the lead up to the $74 billion buyout of Celgene, the big biotech’s leadership did a little housecleaning with a major pact it had forged with Jounce. Out went the $2.6 billion deal and a collaboration on ICOS and PD-1.

Celgene, though, also added a $530 million deal — $50 million up front — to get the worldwide rights to JTX-8064, a drug that targets the LILRB2 receptor on macrophages.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,200+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck wins a third FDA nod for an­tibi­ot­ic; Mereo tack­les TIG­IT with $70M raise in hand

Merck — one of the last big pharma bastions in the beleaguered field of antibiotic drug development — on Friday said the FDA had signed off on using its combination drug, Recarbrio, with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. The drug could come handy for use in hospitalized patients who are afflicted with Covid-19, who carry a higher risk of contracting secondary bacterial infections. Once SARS-CoV-2, the virus behind Covid-19, infects the airways, it engages the immune system, giving other pathogens free rein to pillage and plunder as they please — the issue is particularly pertinent in patients on ventilators, which in any case are breeding grounds for infectious bacteria.